CA-TIGO-ENERGY
18.3.2020 14:02:06 CET | Business Wire | Press release
Tigo Energy, Inc.® , pioneer of the smart modular Flex MLPE, today announced a new addition to the add-on TS4 Platform - the TS4-A-S . This add-on safety solution brings the solar market’s only module-level power electronic (MLPE) multivendor UL-system-certified solution for rapid shutdown. Tigo’s safety solution complies with NEC 2014, 2017, and 2020 with more than 100 inverters for residential, commercial & industrial, and utility customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200318005094/en/
The TS4-A-S provides module-level shutdown when installed on each PV module and accompanied by the Tigo Access Point (TAP) and the Cloud Connect Advanced (CCA). DC production data can be analyzed via Tigo’s SMART Website or App when connected to the cloud. This TS4-A-S launch accompanies the recently announced TS4-A-M (Monitoring Add-on) launch earlier this month . These units complete Tigo’s transition from the legacy TS4-R retrofit platform to the TS4-A add-on platform with mechanical upgrades, UHD-Core technology, expanded specifications to support PV modules up to 500W. To learn more, join Tigo's free online "Rapid Shutdown featuring the TS4-A-S & NEC 2020 " webinar on Thursday, March 26th at 10am PT.
The highlights of the new TS4-A-S (Safety Add-on) with rapid shutdown include:
- Comply with NEC 2014, 2017, 2020 rapid shutdown requirements
- Choose compatibility from more than 100 UL-system-certified inverters
- Choose compatibility from any module up to 500W
- Manual or automatic shutdown in event of AC grid loss
- Automatic email or SMS alerts about faults or operational issues
- Protect PV system assets with full visibility of performance
- Lower O&M costs when identifying specific module problems
- Utilize module manufacturer warranties when tracking module failures
“Only inverters and rapid shutdown devices that have been UL-certified as a system are certified as safe. There’s one multivendor solution for residential C&I – and that’s Tigo,” says Danny Eizips, VP of Hardware Engineering at Tigo. “Others might not meet mandatory safety requirements, and therefore, cannot be trusted as safe when installed together in one PV system. We're working diligently to educate our partners and customers worldwide to know the difference for the safest solar experience.”
Tigo is now taking orders for the TS4-A-S worldwide. The last inventory of legacy TS4-R-S units may be shipped per the discretion of Tigo and Tigo’s distribution partners as the new TS4-A-S shipments are prepared. Both units are fully backward compatible. For price and delivery, consult your preferred solar distributor , call Tigo at +1.408.402.0802, email sales@tigoenergy.com , or visit www.tigoenergy.com .
About Tigo Energy, Inc.
Tigo is a Silicon Valley company founded in 2007 by a team of experienced technologists. Combining a unique systems-level approach with expertise in semiconductors, power electronics, and solar energy, the Tigo team developed the first-generation Smart Module Optimizer technology for the solar industry. Tigo's vision is to leverage integrated and retrofitted Flex MLPE and communications technology to drive the cost of solar electricity down. By partnering with tier 1 module and inverter manufacturers in the industry, Tigo is able to focus on its key innovation with the smartest TS4 modular platform and leverage the broader ecosystem. Tigo has operations in the USA, Europe, Latin America, Japan, China, Australia, and the Middle East. Visit www.tigoenergy.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200318005094/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom